000028 Stock Overview
China National Accord Medicines Corporation Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
My Notes
Capture your thoughts, links and company narrative
China National Accord Medicines Corporation Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥30.39 |
| 52 Week High | CN¥42.13 |
| 52 Week Low | CN¥23.84 |
| Beta | 0.40 |
| 1 Month Change | 3.09% |
| 3 Month Change | 4.76% |
| 1 Year Change | 4.83% |
| 3 Year Change | 6.83% |
| 5 Year Change | -14.47% |
| Change since IPO | 1,145.20% |
Recent News & Updates
Lacklustre Performance Is Driving China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Low P/E
Nov 18
China National Accord Medicines Corporation Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Oct 30China National Accord Medicines (SZSE:000028) Seems To Use Debt Quite Sensibly
Oct 10Recent updates
Lacklustre Performance Is Driving China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Low P/E
Nov 18China National Accord Medicines Corporation Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Oct 30China National Accord Medicines (SZSE:000028) Seems To Use Debt Quite Sensibly
Oct 10China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Low P/E No Reason For Excitement
Aug 13Estimating The Intrinsic Value Of China National Accord Medicines Corporation Ltd. (SZSE:000028)
Jul 12Is China National Accord Medicines (SZSE:000028) A Risky Investment?
Jun 12Improved Earnings Required Before China National Accord Medicines Corporation Ltd. (SZSE:000028) Shares Find Their Feet
May 12Analysts Are Updating Their China National Accord Medicines Corporation Ltd. (SZSE:000028) Estimates After Its Full-Year Results
Apr 10China National Accord Medicines Corporation Ltd. (SZSE:000028) Shares Could Be 28% Below Their Intrinsic Value Estimate
Mar 15China National Accord Medicines (SZSE:000028) Has A Rock Solid Balance Sheet
Feb 29Shareholder Returns
| 000028 | CN Healthcare | CN Market | |
|---|---|---|---|
| 7D | 1.6% | -2.4% | -0.5% |
| 1Y | 4.8% | -11.6% | 9.2% |
Return vs Industry: 000028 exceeded the CN Healthcare industry which returned -11.6% over the past year.
Return vs Market: 000028 underperformed the CN Market which returned 9.2% over the past year.
Price Volatility
| 000028 volatility | |
|---|---|
| 000028 Average Weekly Movement | 5.7% |
| Healthcare Industry Average Movement | 8.4% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 000028 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 000028's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 39,449 | Zhaoxiong Lin | www.szaccord.com.cn |
China National Accord Medicines Corporation Ltd. engages in the retail and distribution of pharmaceutical products in China and internationally. it offers drugs, medical equipment, cargo transportation, warehousing, loading and unloading, glass instruments, cosmetics, sales of daily necessities, other business services, other professional consulting, and self-management services; agent services; import and export of various commodities and technologies; and house leasing services.
China National Accord Medicines Corporation Ltd. Fundamentals Summary
| 000028 fundamental statistics | |
|---|---|
| Market cap | CN¥15.71b |
| Earnings (TTM) | CN¥1.48b |
| Revenue (TTM) | CN¥75.36b |
11.5x
P/E Ratio0.2x
P/S RatioIs 000028 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 000028 income statement (TTM) | |
|---|---|
| Revenue | CN¥75.36b |
| Cost of Revenue | CN¥66.75b |
| Gross Profit | CN¥8.61b |
| Other Expenses | CN¥7.13b |
| Earnings | CN¥1.48b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.65 |
| Gross Margin | 11.42% |
| Net Profit Margin | 1.96% |
| Debt/Equity Ratio | 19.9% |
How did 000028 perform over the long term?
See historical performance and comparisonDividends
2.2%
Current Dividend Yield26%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 23:13 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
China National Accord Medicines Corporation Ltd. is covered by 26 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lei Tian | AJ Securities Co., Ltd |
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Yanyin Zhu | China International Capital Corporation Limited |